Astellas Institute for Regenerative Medicine.

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more

stem-cell-news-pigs-organ-transplants

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses …

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »

Brief update from Bob Lanza on Astellas stem cell program

Lanza-Astellas

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial …

Brief update from Bob Lanza on Astellas stem cell program Read More »